Acupuncture combined with Chinese medicine reduces cancer pain intensity compared to usual care in a meta-analysis of 884 patients

This systematic review and meta-analysis examined the efficacy of acupuncture combined with Chinese medicine for managing cancer pain. The analysis pooled data from studies involving a total sample size of 884 cancer patients. The intervention consisted of acupuncture combined with Chinese medicine. The comparator groups included acupuncture alone, analgesic therapy, or other usual care. The setting details were not reported in the provided data. The primary outcome measured was the reduction in cancer pain intensity.

The results indicated a statistically significant decrease in pain intensity. The mean difference was 1.22 points with a 95% CI of 1.12 to 1.32. This finding suggests that the combined therapy is associated with better pain control than the comparators. The direction of the effect was a decrease in pain scores.

Secondary outcomes showed favorable trends for the combined intervention. The onset time of analgesics was shortened by a mean difference of -14.82 points, with a 95% CI of -16.80 to -12.82. Additionally, the duration of analgesia increased by a mean difference of 2.40 points, with a 95% CI of 2.01 to 3.82. Quality of life also improved with a mean difference of 4.68 points and a 95% CI of 3.69 to 5.66.

Safety and tolerability data were not reported in the available evidence. There were no specific adverse events, serious adverse events, discontinuations, or tolerability rates provided. This lack of safety reporting is a notable gap in the current literature regarding this specific intervention.

The causality note indicates an association of acupuncture combined with Chinese medicine with reduction in cancer pain. The evidence does not establish a definitive causal relationship. The certainty of the evidence is limited by the lack of reported safety data and the specific nature of the included studies. Prior landmark studies in this area often focus on acupuncture alone or standard pharmacotherapy, making direct comparison difficult without more granular data.

Key methodological limitations include the absence of reported safety outcomes and the potential for heterogeneity in the definition of Chinese medicine components across studies. Potential biases may exist due to the lack of detailed setting information and the reliance on observational or non-randomized data sources. These limitations affect the strength of the conclusions that can be drawn for clinical practice.

Clinical implications suggest that clinicians may consider acupuncture combined with Chinese medicine as an adjunctive option for cancer pain management. However, the absence of safety data means that patients should be monitored closely if this approach is adopted. Questions remain unanswered regarding long-term safety, optimal dosing protocols, and the specific components of Chinese medicine that contribute to the observed effects.

In summary, the meta-analysis provides evidence of pain reduction and quality of life improvement. The specific numbers support the efficacy signal, but the lack of safety reporting and the association-based causality note require a conservative approach. Clinicians should weigh these benefits against the unknown safety profile and the limitations of the current evidence base.